{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:28:13Z","timestamp":1764192493281},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>New treatment options have been studied over the last several years, with a recent approval, a first for Beh\u00e7et syndrome, in the United States. New management guidelines have also been published, helping with this nowadays more commonly recognized condition's management. The goal of this review is to summarize the most important and potentially clinically relevant recent developments and discuss their impact in the management of patients with Beh\u00e7et syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Apremilast is now approved for the treatment of oral ulcer of Beh\u00e7et syndrome in the United States. It's possible benefits in controlling nonoral ulcer features of the syndrome are awaited. Long-term use of tumor necrosis factor inhibitors for the treatment of especially eye disease in Beh\u00e7et syndrome seems to be safe and efficacious. New treatment options such as ustekinumab, secukinumab, tocilizumab and others have early promising data but more studies are needed to better clarify their role in Beh\u00e7et management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The last 2 years have not only seen the approval of the first drug specifically labeled for the treatment of Beh\u00e7et syndrome in the case of apremilast, many groups have also presented and published their findings on promising new therapeutic agents, which may soon be added to our tools in treating this condition. We also know more about other drugs, such as tumor necrosis factor inhibitors as many patients have been on these for long periods of time, and long-term follow-up data seem to confirm their role in Beh\u00e7et treatment. Lack of placebo controlled, randomized trials, for the most part, are still outstanding issues.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000666","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T15:45:51Z","timestamp":1571067951000},"page":"35-40","source":"Crossref","is-referenced-by-count":15,"title":["Management of Beh\u00e7et syndrome"],"prefix":"10.1097","volume":"32","author":[{"given":"Yusuf","family":"Yazici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230901","first-page":"808","article-title":"2018 Update of the EULAR recommendations for the management of Behcet's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R2-20230901","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.14690","article-title":"Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Beh\u00e7et's disease","author":"Kinoshita","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"R3-20230901","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1002\/art.40531","article-title":"Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Behcet's syndrome","volume":"70","author":"Emmi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/rheumatology\/key242","article-title":"Management of major organ involvement of Behcet's syndrome: a systematic review for update of the EULAR recommendations","volume":"57","author":"Ozguler","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behcet's disease: a large-scale, long-term postmarketing surveillance in Japan","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"R7-20230901","doi-asserted-by":"crossref","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et's disease, national multicenter study of 177 cases","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10067-018-4228-6","article-title":"Comparative efficacy between adalimumab and infliximab in the treatment of noninfectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients","volume":"38","author":"Fabiani","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R9-20230901","first-page":"1","article-title":"Comparison of the treatment results for Beh\u00e7et uveitis in patients treated with infliximab and interferon","volume":"3","author":"Yal\u00e7indag","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/art.40235","article-title":"Brief report: drug-free long-term remission in severe Beh\u00e7et's disease following withdrawal of successful antitumor necrosis factor treatment","volume":"69","author":"Sfikakis","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Behcet's disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J Autoimmun"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/art.40912","article-title":"Long term outcome of ustekinumab therapy for Beh\u00e7et's disease","volume":"71","author":"Mirouse","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"108113","DOI":"10.1016\/j.jaut.2018.09.002","article-title":"Efficacy of the anti-IL 17 secukinumab in refractory Behcet's syndrome: a preliminary study","volume":"97","author":"Di Scala","year":"2019","journal-title":"J Autoimmun"},{"key":"R15-20230901","first-page":"239","article-title":"Secukinumab induced Behcet's syndrome: a report of two cases","volume":"5","author":"Dincses","year":"2019","journal-title":"Oxf Med Case Reports"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2014.01.014","article-title":"Criteria for Beh\u00e7et's disease with reflections on all disease criteria","volume":"48\u201349","author":"Yazici","year":"2014","journal-title":"J Autoimmun"},{"key":"R17-20230901","first-page":"2057","article-title":"Tocilizumab in the treatment of severe and\/or refractory vasculo-Behcet's disease: a single-centre experience in China","volume":"57","author":"Ding","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20230901","article-title":"Efficacy of apremilast for oral ulcers associated with active Behcet's syndrome over 28 weeks: results from a phase 3 study","author":"Hatemi","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","article-title":"Apremilast for Behcet's syndrome \u2013 a phase 2, placebo-controlled study","volume":"372","author":"Hatemi","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T01:06:23Z","timestamp":1693530383000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000666","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}